RxDoctor Payments Data

Euriko Torrazza Perez

Gastroenterology · Albuquerque, NMNPI 1033377221

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,223, 2.1 times the $578 reported in 2019.

$4,658in general payments, 2019–2025

Across 148 payments — averaging $31.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$842
  • Takeda Pharmaceuticals U.S.A., Inc.$667
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$622
  • AbbVie$608
  • Ardelyx, Inc.$267
  • Intercept Pharmaceuticals, Inc.$207
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,658100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,658 in reported general payments places this provider in the 75th percentile of 81 gastroenterology providers in New Mexico.

See all gastroenterology providers in New Mexico

Medicare billing

Part B allowed, 2024
$54,442
Medicare patients
277
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$43,971
Ursodiol39$3,764
Azathioprine13$1,536
Lactulose15$984
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl43$916
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl19$469
Omeprazole16$385
Spironolactone14$204
Prednisone14$104
Furosemide18$97
Ondansetron OdtOndansetron11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$622$43,97114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 gastroenterology providers in New Mexico.

Other gastroenterology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →